Literature DB >> 28231541

Endogenous microRNA-424 predicts clinical outcome and its inhibition acts as cancer suppressor in human non-small cell lung cancer.

Yu Wang1, Zhenyang Lv1, Junfeng Fu1, Ze Wang1, Zhe Fan1, Ting Lei2.   

Abstract

PURPOSE: We examined the expression, clinical correlation and functional mechanisms of endogenous microRNA-424 (miR-424) in human non-small cell lung cancer (NSCLC).
METHODS: Expression pattern of endogenous miR-424 was examined by qRT-PCR in clinical samples obtained from 233 NSCLC patients. Correlations between differential miR-424 expression level (low vs. high) and NSCLC patients' clinicopathological parameters or survival were statistically examined. In in vitro NSCLC H596 and SW900 cells, miR-424 was either upregulated or downregulation by lentiviral transduction. Their effects on cancer cell viability, proliferation, and cell-cycle transition were also examined.
RESULTS: MiR-424 expression was not different between NSCLC tumors and healthy lung tissues. However, it is much upregulated in NSCLC tumors associated with patients at advanced clinical stages. Statistical analyses demonstrated that high endogenous miR-424 expression in NSCLC tumors was significantly correlated with patients' advanced clinical stages, aggressive tumor metastasis, and short survival. In addition, Cox regression model predicted that endogenous miR-424 might be an independent prognostic marker in NSCLC. In in vitro NSCLC cell lines, miR-424 downregulation had a significant suppressing effect on cancer proliferation and G1 to S phase cell-cycle transition. On the other hand, miR-424 upregulation had no effect on NSCLC in vitro.
CONCLUSION: High endogenous miR-424 expression in tumors may predict poor prognosis of patients with NSCLC. Inhibiting endogenous miR-424 may also serve an effective cancer suppressor in NSCLC.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Clinical outcome; Lentivirus; NSCLC; Prognosis; Survival; miR-424; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28231541     DOI: 10.1016/j.biopha.2017.01.163

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Ke Zhao; Jing Cheng; Baojun Chen; Qi Liu; Di Xu; Yongjian Zhang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

2.  Long Non-coding RNA PVT1 Competitively Binds MicroRNA-424-5p to Regulate CARM1 in Radiosensitivity of Non-Small-Cell Lung Cancer.

Authors:  Dong Wang; Yi Hu
Journal:  Mol Ther Nucleic Acids       Date:  2018-12-15       Impact factor: 8.886

3.  HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.

Authors:  Meng Yu; Toshinori Ozaki; Dan Sun; Haotian Xing; Baojun Wei; Jun An; Jieping Yang; Ying Gao; Shuangjie Liu; Chuize Kong; Yuyan Zhu
Journal:  J Exp Clin Cancer Res       Date:  2020-06-10

4.  Long Noncoding RNA CCAT2 Knockdown Suppresses Tumorous Progression by Sponging miR-424 in Epithelial Ovarian Cancer.

Authors:  Fu Hua; Chang-Hua Li; Xiao-Gang Chen; Xiao-Ping Liu
Journal:  Oncol Res       Date:  2017-05-21       Impact factor: 5.574

5.  Ropivacaine inhibits proliferation, migration, and invasion while inducing apoptosis of glioma cells by regulating the SNHG16/miR-424-5p axis.

Authors:  Rong Liu; Min Wu; Guiju Xu; Lu Ju; Jinhui Xiao; Wei Zhong; Xiao He; Yan Yang
Journal:  Open Life Sci       Date:  2020-12-31       Impact factor: 0.938

6.  TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression.

Authors:  Yapei Huang; Yan Xie; Peter W Abel; Peng Wei; Jocelyn Plowman; Myron L Toews; Heather Strah; Aleem Siddique; Kristina L Bailey; Yaping Tu
Journal:  Biochem Pharmacol       Date:  2020-07-24       Impact factor: 5.858

7.  Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression.

Authors:  Jing Zhang; Hui Liu; Lidan Hou; Ge Wang; Rui Zhang; Yanxia Huang; Xiaoyu Chen; Jinshui Zhu
Journal:  Mol Cancer       Date:  2017-09-11       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.